Clinical Trials Directory

Trials / Completed

CompletedNCT05647915

Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and NAFLD

Assess the Effects of Berberine in Reducing Abdominal Visceral Adipose Tissue Among Individuals with Obesity and Non-alcoholic Fatty Liver Disease

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
337 (actual)
Sponsor
China National Center for Cardiovascular Diseases · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine in reducing visceral and liver adipose tissue among individuals with obesity and non-alcoholic fatty liver disease (NAFLD) in China.

Detailed description

The trial aims to evaluate the efficacy and safety of berberine treatment for obesity and NAFLD. Potential eligible patients will be recruited from 10-20 medical centers in China. After a 4-week run-in period with berberine, all the eligible participants will be randomized (1:1) to berberine 1.0 g per day plus lifestyle intervention (Arm A) or placebo plus lifestyle intervention (Arm B). The participants will be asked to attend the visit at least once every 2 months, and be followed up for 6 months.

Conditions

Interventions

TypeNameDescription
DRUGBerberine plus lifestyle interventionberberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention. Lifestyle intervention is based on "Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update)" and "China Blue Paper on Obesity Prevention and Control", including health education on diet, physical activity and weight loss, etc.
BEHAVIORALPlacebo plus lifestyle interventionPlacebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention. Lifestyle intervention is based on "Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update)" and "China Blue Paper on Obesity Prevention and Control", including health education on diet, physical activity and weight loss, etc.

Timeline

Start date
2023-07-06
Primary completion
2024-08-09
Completion
2024-08-09
First posted
2022-12-13
Last updated
2025-01-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05647915. Inclusion in this directory is not an endorsement.